
    
      This is a prospective, multisingle-center, single-arm study to establish the safety and
      feasibility of BBB disruption along the periphery of tumor resection cavity using the
      ExAblate Neuro Model 4000 Type 2.0 (220 kHz) system. For this study, patients will be
      eligible to enroll in the study prior to beginning the planned adjuvant TMZ chemotherapy
      phase of treatment. Of note, only patients who are deemed eligible for adjuvant TMZ will be
      eligible for enrollment. This study will enroll up to 20 subjects.
    
  